By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Peptides are presented in a new report. According to news reporting originating from Madison, Wisconsin, by NewsRx correspondents, research stated, "Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) that is often resistant to standard therapies. Resveratrol suppresses MTC growth in vitro, but it has low bioavailability in vivo due to its poor water solubility and rapid metabolic breakdown, as well as lack of tumor-targeting ability."
Our news editors obtained a quote from the research from the University of Wisconsin, "A novel unimolecular micelle based on a hyperbranched amphiphilic block copolymer was designed, synthesized, and characterized for NET-targeted delivery. The hyperbranched amphiphilic block copolymer consisted of a dendritic BoltornŽ H40 core, a hydrophobic poly(l-lactide) (PLA) inner shell, and a hydrophilic poly(ethylene glycol) (PEG) outer shell. Octreotide (OCT), a peptide that shows strong binding affinity to somatostatin receptors, which are overexpressed on NET cells, was used as the targeting ligand. Resveratrol was physically encapsulated by the micelle with a drug loading content of 12.1%. The unimolecular micelles exhibited a uniform size distribution and spherical morphology, which were determined by both transmission electron microscopy (TEM) and dynamic light scattering (DLS). Cellular uptake, cellular proliferation, and Western blot analyses demonstrated that the resveratrol-loaded OCT-targeted micelles suppressed growth more effectively than non-targeted micelles. Moreover, resveratrol-loaded NET-targeted micelles affected MTC cells similarly to free resveratrol in vitro, with equal growth suppression and reduction in NET marker production."
According to the news editors, the research concluded: "These results suggest that the H40-based unimolecular micelle may offer a promising approach for targeted NET therapy."
For more information on this research see: Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale, 2013;5(20):9924-33. (Royal Society of Chemistry - www.rsc.org/; Nanoscale - pubs.rsc.org/en/journals/journalissues/nr)
The news editors report that additional information may be obtained by contacting W. Xu, Dept. of Biomedical Engineering, Wisconsin Institutes for Discovery, University of Wisconsin-Madison, Madison, WI 53715, United States. Additional authors for this research include J.F. Burke, S. Pilla, H. Chen, R. Jaskula-Sztul and S. Gong (see also Peptides).
Keywords for this news article include: Cancer, Madison, Therapy, Oncology, Wisconsin, Octreotide, United States, Cyclic Peptides, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC